Texas Instruments continues to build a patent portfolio focusing on control signals and semiconductors
Texas Instruments Inc. is an electronics company headquartered in Dallas, TX, and one of the world’s largest manufacturers and suppliers of semiconductors, such as chips for cellular handsets and digital signal processors…Read more
MicroBiome Therapeutics Receives Notice Of Allowance For U.S. Patent Covering Glyceollin As A Treatment For Diabetes And Obesity
MicroBiome TherapeuticsTM LLC, (MBT) today reported that the U.S. Patent and Trademark Office has issued a notice of allowance for the company’s patent application covering the use of glyceollin to treat diabetes and obesity.MBT is investigating glyceollins for the treatment of metabolic disorders, including diabetes and obesity, as well as their potential role in modulating the gastrointestinal microbiome. MBT also announced that it is participating in the One-on-One Partnering sessions of the 17thAnnual BIO CEO and Investor Conference being held this week in New York City.
Glyceollin I, II, and III are small molecule natural products made by soy plants under certain environmental conditions to help combat infectious organisms and other stressors. In animal studies, glyceollins have demonstrated activity in a number of human disease models, including breast and ovarian cancer, hypercholesterolemia, and metabolic disorders.
Beware so-called “free trade” with the US: Australia
Peter Drysdale, Editor of the East Asia Forum, has written a stinging rebuke of the Australia-US Free Trade Agreement (AUSFTA), which he claims has come at a high price to Australia, and also cautioned against the US-led Trans-Pacific Partnership (TPP) agreement, which is currently being negotiated between the US and 11 other nations (including Australia).
Drysdale makes some salient points about the AUSFTA. The agreement is likely to have been welfare destroying for a number of reasons. First, as argued by Drysdale, the AUSFTA is likely to have caused trade diversion, which occurs when an importing country shifts its buying from a more efficient, lower cost country whose goods are subject to a tariff towards the less efficient and higher cost FTA partner whose goods are not subject to a tariff…Read more
Qualcomm to pay China $1 billion in antitrust settlement
Qualcomm is expected to pay a record fine of $1 billion to the Chinese government in order to end a 14-month antitrust probe, according to reports.
The US chipmaker has held recent talks with Chinese investigators to come to a settlement of the dispute, in which China alleges Qualcomm’s licensing practices are anti-competitive. According to Reuters, a source close to the matter said the tech giant is likely to pay a record-breaking fine of $1 billion to close the case…Read more
Japan to lower trademark, patent registration fees
The Japan Patent Office said Tuesday it plans to lower trademark and patent registration fees to cut the load on domestic companies amid competition from their foreign rivals and enhance trademark and patent protection.
The office intends to submit a bill to the Diet during the current session in a bid to implement the cut next year.
It plans to lower the trademark registration fee 25 percent from the present ¥37,600 ($317) per business category to ¥28,200 and the fee for renewal 10 years after registration from ¥48,500 to ¥38,800…Read more
Venus Remedies bags Indian Patent for Vancoplus
Vancoplus projected to cater to a market of Rs 214 crore in India by 2018-19
Venus Remedies, an R&D-driven global pharmaceutical company working on innovative medicines in the anti-infective and oncology segments, has received a product patent grant for its unique antibiotic research product, Vancoplus, from the Indian Patent Office (IPO). The patent is valid till 2025.
Commenting on the achievement, Dr Manu Chaudhary, Joint Managing Director, Venus Remedies and Director, Research, Venus Medicine Research Centre (VMRC), the company’s R&D wing said, “It took the VMRC more than seven years to develop this product. It is one of the best and safest options to get rid of drug-resistant gram-negative and gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA).”…Read more
IAM to partner with Beijing regional government to host special IPBC China in April
In an exciting new development for IAM and the IPBC brand, we are currently in the process of organizing a special IPBC China in Beijing with the support of the Haidian District Government and in partnership with the Haidian IP Cooperation Organization.
Taking place on 21st and 22nd April, IPBC China 2015 is designed to address some of the major IP challenges now confronting corporate Chinese IP leaders and policymakers, but will also be open to international delegates on an invitation-only basis.
This is the first time we have organized an IPBC with the support of the Chinese authorities and we are delighted to be working with them to produce what we believe will be a truly memorable educational and networking event…Read more
Patent dispute threatens Xiaomi’s India future
Patent disputes between Xiaomi, an emerging smartphone maker in China, and Swedish telecom company Ericsson continue after Ericsson claimed Xiaomi violated an order from Delhi High Court on Feb 5.
In December the Indian court banned Xiaomi from selling phones in India as it found the company did not pay royalties to Ericsson, which owns patents for technology used in Xiaomi phones.
At the court hearing on Feb 5, Ericsson claimed that Xiaomi continued to sell phones that used its patented technology in India through a website called xiaomishop.com.
Xiaomi denied the accusation and said it did not authorize the website to sell its products. The phone maker said it had nothing to do with the e-commerce website, which it alleged infringed Xiaomi’s brand rights and was ordered to stop selling Xiaomi products.
In December, Ericsson sued Xiaomi in India, claiming it violated its patent rights. Delhi High Court ordered Xiaomi and its local e-commerce partner Flipkart to stop selling handsets in India until Feb 5, when the court was due to hear Ericsson’s patent-infringement case, Indian media reported…Read more
Author :
TT Consultants
